PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32009091-1	2020	Objective A randomized controlled trial has shown the efficacy of thalidomide against Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; however, there are still refractory patients.	Thalidomide	66-77	myomesin 2	Homo sapiens	132-141	
21890654-7	2011	Of note, in our study, combination therapy of bortezomib and thalidomide successfully improved the condition of the patient with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes syndrome associated with multicentric Castleman"s disease, suggesting that the combination therapy may be an effective therapeutic strategy for the intractable polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes syndrome associated with multicentric Castleman"s disease.	Thalidomide	61-72	myomesin 2	Homo sapiens	175-184	
21890654-7	2011	Of note, in our study, combination therapy of bortezomib and thalidomide successfully improved the condition of the patient with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes syndrome associated with multicentric Castleman"s disease, suggesting that the combination therapy may be an effective therapeutic strategy for the intractable polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes syndrome associated with multicentric Castleman"s disease.	Thalidomide	61-72	myomesin 2	Homo sapiens	408-417	
15086832-8	2004	The concentration of M-protein in the serum or urine of seven of the 11 patients was reduced by at least 30% after thalidomide treatment, and MVD in the BM decreased in three of these seven cases in response to thalidomide.	Thalidomide	115-126	myomesin 2	Homo sapiens	21-30	
15086832-8	2004	The concentration of M-protein in the serum or urine of seven of the 11 patients was reduced by at least 30% after thalidomide treatment, and MVD in the BM decreased in three of these seven cases in response to thalidomide.	Thalidomide	211-222	myomesin 2	Homo sapiens	21-30	
15479647-7	2004	However, in 2 cases in which the mean blood concentration of thalidomide was 2 microg/mL or higher, an M-protein-reducing effect was not obtained.	Thalidomide	61-72	myomesin 2	Homo sapiens	103-112	
12190011-12	2002	Thalidomide plus dexamethasone was given to 9 patients who did not respond to thalidomide alone, and in 6 of them a reduction of M-protein was then observed.	Thalidomide	0-11	myomesin 2	Homo sapiens	129-138